NCT02471833View on ClinicalTrials.gov

Health Evaluation in African Americans Using RAS Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

April 15, 2022

Study Completion Date

April 15, 2022

Conditions
Alzheimer's Disease
Interventions
DRUG

Telmisartan 20mg

Participants will be given 20 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.

DRUG

Telmisartan 40mg

Participants will be given 40 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.

DRUG

Placebo

Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.

Trial Locations (1)

30322

Emory University, Atlanta

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Emory University

OTHER

NCT02471833 - Health Evaluation in African Americans Using RAS Therapy | Biotech Hunter | Biotech Hunter